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Abstract
Self-templating propagation of protein aggregate conformations is increasingly becoming a
significant factor in many neurological diseases. In Alzheimer disease (AD), intrinsically
disordered amyloid-β (Aβ) peptides undergo aggregation that is sensitive to environmental
conditions. High-molecular weight aggregates of Aβ that form insoluble fibrils are deposited as
senile plaques in AD brains. However, low-molecular weight aggregates called soluble
oligomers are known to be the primary toxic agents responsible for neuronal dysfunction. The
aggregation process is highly stochastic, and involves both homotypic (Aβ-Aβ) and heterotypic
(Aβ with interacting partners) interactions. Two of the important members of interacting partners
are membrane lipids and surfactants, to which Aβ shows a perpetual association. Aβ–membrane
interactions have been widely investigated for more than two decades, and this research has
provided a wealth of information. Although this has greatly enriched our understanding, the
objective of this review is to consolidate the information from the literature that collectively
showcases the unique phenomenon of surfactant-mediated Aβ oligomer generation, which has
largely remained inconspicuous. This is especially important because Aβ aggregate ‘strains’ are
increasingly becoming relevant in light of the correlations between the structure of aggregates
and AD phenotypes. Here, we will focus on aspects of Aβ-surfactant interactions specifically
from the context of how surfactant modulation generates a wide variety of biophysically and
biochemically distinct oligomer sub-types. This, we believe, will refocus our thinking on the
influence of surfactants and open new approaches in delineating the mechanisms of AD
pathogenesis.
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Aβ and Alzheimer disease pathology
Alzheimer disease (AD) is a fatal, progressive neurodegenerative disorder with clinical
manifestations that include acute memory loss, cognitive decline and behavioral changes
resulting in social inappropriateness. AD is the most common among all neurodegenerative
disorders, with over five million people affected in the United States alone [1]. Without
medicinal intervention, this number is expected to nearly triple by 2050 [1]. According to the US
Centers for Disease Control (CDC), the death rates from AD dramatically climbed to 55%
between 1999 and 2014, making viable diagnostic and therapeutic avenues a critical need [2].
Discovered by the Bavarian psychiatrist Alois Alzheimer in 1905, significant advancements in
understanding AD only began to occur 7-8 decades later with the morphological understanding
of two main pathological hallmark lesions in the AD brain: extracellular neuritic plaques and
intracellular neurofibrillary tangles. During the 1990s it became clear that two proteins, amyloidβ (Aβ) and hyperphosphorylated tau, are the major components of plaques and tangles,
respectively [3, 4].
Aβ is generated by the proteolytic processing of amyloid precursor protein (APP), which
is abundant in the central nervous system but ubiquitously expressed in many cell types [5, 6].
APP is an integral membrane protein containing a single transmembrane domain, and the
cleavage occurs sequentially by the aspartyl proteases, β- and γ-secretases (Figure 1). While βsecretase cleaves APP on the extracellular side, the γ-secretase complex hydrolyzes the protein
within the transmembrane domain (Figure 1). The γ-secretase complex comprises the proteins
Aph-1, presenelin-1 (PS1), presenelin-2 (PS2), and nicastrin, and has a broader specificity in
cleavage that leads to the generation of multiple Aβ isoforms ranging from Aβ1-38 to Aβ1-43
[7]. The cleavage specificity of the γ-secretase complex is also controlled by genetic mutations in
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APP; however, the precise mechanism of the enzyme remains uncertain [8]. Among the
isoforms, Aβ1-40 (Aβ40) is the predominant form followed by Aβ1-42 (Aβ42), but the latter is
initially observed in diffuse amyloid aggregates [9] and is believed to be responsible for early
synaptic and neuronal dysfunction in AD brains.

Aggregation of Aβ and significance of pathways
Spatiotemporal profile of Aβ aggregation. Upon cleavage from APP by aspartyl
proteases, Aβ peptide is mainly released from the membrane into the extracellular matrix. The
newly generated Aβ is intrinsically disordered, which is reflected in its random coil
conformation [10-12]. The monomeric Aβ is highly susceptible to aggregating with other Aβ
molecules, and does so almost spontaneously upon its generation from APP. Aggregation of Aβ
is a nucleation-dependent process that follows a sigmoidal growth kinetics with the formation of
a critical mass of aggregates called nucleus, being obligatory for the emergence of mature fibrils
(Figure 2). A schematic of homotypic Aβ aggregation shows three broadly-defined phases of
aggregation, namely a lag phase (I), growth phase (II) and a saturation phase (III) (Figure 2). The
lag phase of aggregation is perhaps the most important phase during aggregation from a
physiological perspective, as elaborated later in this manuscript, and is mechanistically the most
confounding of all the phases. Although there is consensus regarding the formation of a nucleus
during the lag phase, uncertainty remains about the nature of nucleus; whether it is
heterogeneous or homogenous [13], or whether there is a single nucleation event or multiple
events [14-17]. In sum, one could describe the lag phase of aggregation as being in dynamic flux
dominated by stochastic interactions between Aβ conformeric ensembles until an ordered,
relatively stable nucleus (or nuclei) is (are) formed. Once the prerequisite and a critical aggregate
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size is achieved (I in Figure 2), the propagation phase ensues with forward rates involving
predominantly aggregate – monomer interactions that result in an exponential increase in the
rates of aggregation towards high molecular weight protofibrils (II in Figure 2), which then form
insoluble fibrils in the saturation phase (III in Figure 2) [18, 19].
This aggregation mechanism, although consistent with numerous reports, does not
represent the complete picture of the aggregation landscape. As previously described by Radford
and others [20, 21], protein aggregation and amyloid formation in itself is an alternate pathway
during protein folding. In a typical aggregation pathway, smaller oligomers are formed
transiently along the fibril formation pathway that ‘roll down’ the energy landscape towards
energetically favorable fibrils. In reality, even within the energy landscape along the
‘aggregation funnel’ there are many different pathways containing several kinetic traps in which
specific conformeric and structurally variant species could be present. Indeed, it has become
evident that there are alternative pathways and kinetic traps along the aggregation pathway [22,
23], and that neurotoxic oligomers can also be populated via such alternate pathways [24-27]. As
mentioned earlier, the early stages of aggregation (lag phase), being dominated by homotypic
and heterotypic stochastic interactions, could likely contain numerous kinetic traps. An obvious
characteristic of such traps is that the oligomeric aggregates that are formed may differ in their
conformation, degree of aggregation (number of monomers within the assembly), heterogeneity,
or all of these factors. Such differences within these aggregates could manifest in differences in
their ability to seed the propagation of fibrils. Thus, depending on the number of such
conformeric strains, fibrils are formed via different pathways displaying structural heterogeneity
and polymorphism [28]. This has been further elaborated in the concluding sub-section of this
manuscript.
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Aβ aggregate structure and AD phenotypes. Aβ aggregation is strongly driven by both
homotypic (Aβ-Aβ) and heterotypic (Aβ-solvent and/or Aβ-solute) interactions. Because of
stochasticity, the lag phase is highly susceptible to heterotypic interactions with other solutes
present in the system. From years of research, we have known that the Aβ ‘interactome’ includes
a variety of agents such as metal ions [29, 30], protein binding partners [31, 32], natural products
and metabolites [33-37], as well as lipids and surfactants (as elaborated in this article).
Therefore, heterotypic interactions with any Aβ interactome molecules have the potential to
change the conformation of Aβ during the lag phase and alter the pathway of aggregation, which
could result in multiple conformational variants of aggregates with distinct biochemical and
cellular properties. Manifestations of conformational and morphological differences in cellular
toxicity have been established in the past [38, 39]. The significance of Aβ fibril structure and
morphology in AD is becoming far more critical than originally thought. Somewhat similar to
the observations in prion diseases [40, 41], structure-to-phenotype correlations are beginning to
emerge. Recently, using brain-derived fibrils as seeds, the Tycko laboratory has elegantly
established that clinical phenotypic differences, especially those leading to rapid-onset AD
(rAD), could emerge in part from the structure and morphology of the propagating fibrils [42,
43]. Along similar lines, Cohen et al. have reported conformationally-distinct Aβ aggregates in
rAD cases as compared with typical AD [44]. In recent reports by the Jucker and Prusiner
laboratories, the authors revealed structural variations in etiological subtypes of AD brains on the
basis of their ability to bind fluorescent probes [45, 46]. Prion-like propagation of Aβ has now
been well understood from the demonstration that intracerebral injection of endogenous Aβ seeds
induces widespread deposition of Aβ in transgenic mice [47-53]. Inoculations in such
experiments either used Aβ-laden brain homogenates or exogenous fibrils as seeds, and
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therefore, structural diversity of fibril seeds has mainly been attributed to propagation behavior
of the seeds [51, 54, 55].

Lipids and membranes could be important members of the Aβ interactome.
The main focus of this review is to bring forth how lipids and surfactants are able to
modulate the aggregation behavior of Aβ to generate a multitude of structurally and functionally
different aggregates depending on the physiochemical nature of the surfactant. The affinity of Aβ
peptides for membranes becomes obvious when one looks at the generation of the peptides, as
described above. The C-terminal sequence of Aβ within APP is buried in the phospholipid
bilayer, while the N-terminal remains outside. This is reflected in the sequence of the peptide
with the N-terminal side of the peptide containing many polar amino acids and the C-terminus
containing a majority of hydrophobic residues (Figure 2). The amphipathic nature of Aβ
peptides uniquely presents itself to preferential interactions with interfaces such as liquidgaseous (water-air), liquid-solid (solvent-surface) and liquid-liquid (phase separated). In this
context, there is a high likelihood of amphipathic lipids and other surfactants to interact with Aβ
by providing a template for aggregation. When Aβ is released as a soluble monomer, charged
membranes act as two-dimensional aggregation-templates to initiate accumulation of surfaceassociated Aβ, typically to augment aggregation into neurotoxic structures [56].

Interaction and modulation of Aβ aggregation by lipids.
a.

Interactions with bilayer-forming lipids
A wealth of information has been generated from over two decades of research on the

interactions of Aβ with membrane surfactants. The amphipathic Aβ peptide shows strong affinity

7

for membranes, and such heterotypic interactions may affect early steps of Aβ aggregation
significantly [57-62]. First, we will focus on the surfactants (lipids) containing two fatty acid
acyl chains that predominantly form a lipid bilayer. In pathological contexts, lipid membranes,
sub-cellular organelle surfaces, synaptic vesicles, lipid rafts as well as endo- and exosomes can
significantly affect Aβ aggregation by accelerating and nucleating fibril formation, generating
and stabilizing specific oligomers and even promoting polymorphic aggregates.
Interactions leading to pore formation and membrane disruption. One of the widely
investigated phenomena of Aβ-membrane interactions is the insertion of Aβ into the membranes
and subsequent disruption. Importantly, Aβ has been long known to form Ca(II) permeable
channels in the membrane [63, 64]. Association of Aβ with anionic lipid monolayers has been
observed leading to partial insertion of Aβ into the membrane [65]. Such an interaction
consequently promotes aggregation to Aβ fibrils [66]. Investigation of such mechanisms by
Aβ40 using NMR spectroscopy indicated that the N-terminal region is unstructured while the Cterminal hydrophobic region adopts anα-helical conformation [67]. The two regions are
separated by a kink, which is significant in membrane insertion [67]. Molecular dynamics (MD)
simulations to model the interactions between Aβ oligomers and membranes showed formation
of ion channels with two different topologies, suggesting a modulatory effect of the membranes
on Aβ structure and conformation. More importantly, Aβ oligomers have now been widely
understood to form pores in both synthetic as well as cellular membranes, capable of generating
conductance and classical channel activity [64, 68, 69]. Both Aβ monomers reconstituted with
lipids as well as pre-formed oligomers deposited on to synthetic or brain-derived lipids formed
channels [70, 71]. In addition, experimental observation of the effect of this channel on Ca2+
selectivity was supported by such models [72, 73]. Another study using MD simulations on
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Aβ42 peptide monomers and oligomers identified insertion into the lipid bilayer in agreement
with other reports [74]. These theoretical results were also consistent with the experimental
observation that Aβ forms a cation selective channel in both synthetic lipid-bilayers [75] and
cellular membranes[76]. However, it remains unknown whether the all oligomers are able to
form channels in the membrane, and whether oligomer conformation capable of pore formation
is induced by the interaction with lipid surfaces, which that precedes it. Such is the case with
zwitterionic lipids, to which a conserved region (K16-E22) within the central region of Aβ bound
to lipid surface prior to surface-catalyzed Aβ fibril formation and transmembrane pore formation
[77].
Interactions on lipid surfaces. Interactions of Aβ with lipid surfaces have been
investigated by using many different models including solid support, self-assembled monolayers,
and membrane-mimics [78-80]. Many reports indicate that Aβ interactions with the anionic
phospholipids on reconstituted liposomes and unilamillar vesicles are largely limited to the lipid
surface at neutral pH [58, 81, 82]. In one report, anionic phospholipids increased the fibrillation
of Aβ, while neutral, zwitterionic, and lipids lacking phosphate groups did not show significant
effect on Aβ fibrillation rates [83]. Investigation into the effects of surface charges on Aβ
aggregation using zwitterionic (2-dioleoylphosphatidylcholine (DPPC) or 1,2-dioleoyl-snglycero-3 −phosphocholine (DOPC)), anionic (1,2-dioleoyl-sn-glycero- 3–[phospho-rac-(3lysyl(1-glycerol)] (DOPG)) and cationic (1,2- dioleoyl-sn-glycero-3-methylammonium-propane
(DOTAP)) lipids led to the finding that Aβ aggregated in zwitterionic DPPC and anionic DOPG,
while it inserted and disrupted the membranes of cationic DOTAP and zwitterionic DOPC [84].
In one report, aggregation of Aβ on zwitterionic DOPC LUVs by FRET analysis indicated that
the liposomes were able to catalyze fibril formation via secondary nucleation mechanisms
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involving aggregate fragmentation [85]. This report also revealed that the binding on the lipid
surface was restricted to only aggregated Aβ and not the monomer, suggesting secondary
pathways induced by oligomeric forms of Aβ on the membrane surface. In negatively charged
lipids, Aβ40 oligomer binding was dependent on surface charges, while membrane insertion was
dictated by membrane rigidity, and both processes were clearly distinct [86]. MD simulations
involving Aβ peptides and the phospholipid bilayer using DPPC and dioleoyl phosphotidylserine
(DOPS) vesicles showed fibril promotion on the surface of the membrane lipids because of the
peptide re-distribution on the surface via charged interactions, exhibiting an auto-regulation type
behavior [87]. The interactions of Aβ with membranes depend not only on the former’s structure
and conformational state, but also on reaction conditions. Good et al. observed that Aβ-liposome
interactions were higher for Aβ aggregates than monomeric Aβ [88]. They found that Aβ
aggregates bind to both cortical homogenates and membranes, whereas Aβ monomers bind to
homogenates only. However, another report using different experimental conditions revealed that
monomeric Aβ bound rapidly to liposomes, while the Aβ aggregates bind slowly [89]. An MD
simulation study on the interactions of a pre-formed Aβ42 tetramer on POPC membranes
showed that the tetramers were elongated, and changed their overall structure upon interaction
with the membrane surface [90], suggesting that the membrane surface characteristics play an
important role in Aβ aggregate structure. Overall, these reports indicate the surface
characteristics of membranes, which are mainly dominated by the lipid head groups, behave as
specificity inducing factors for Aβ oligomer conformations during aggregation.

10

b.

Interactions of Aβ with micelle-forming lipids
As a rule of thumb, lipids containing a single acyl chain tend to form micelles as opposed

to a bilayer. Similar to the liposomal systems, micelles as membrane-mimicking environments
have also provided a wealth of information on a mechanistic understanding of Aβ – lipid
interactions. Anionic surfactants such as sodium dodecylsulfate (SDS), often used as denaturants,
have been used as model polar-nonpolar interfaces to investigate the aggregation of Aβ and other
amyloid proteins [67, 91-95]. Yamamoto and colleagues investigated the effect of neutral,
zwitterionic and anionic surfactants on Aβ aggregation and found that all three surfactants were
able to augment Aβ40 and Aβ42 aggregation in a concentration-dependent manner [92]. The
effects of surfactants on the two peptides varied, with Aβ42 showing more pronounced
aggregation than Aβ40. More importantly, the aggregation behavior of the peptides showed
strong dependence on surfactant concentration. Only in a narrow range of concentrations below
its critical micelle concentration (CMC), SDS was able to augment Aβ42 aggregation without
any observable lag time [92]. Based on the idea that micellar interfaces uniquely affect Aβ
aggregation, Nichols and coworkers demonstrated the phenomena of interfacial aggregation
using model interfaces composed of dilute hexafluoro isopropanol (HFIP) as well as bufferchloroform [96, 97]. They elegantly showed that Aβ aggregation is preferentially augmented at
the polar – non-polar interfaces. Similar to Yamamoto and co-workers, Rangachari et al. also
demonstrated that SDS accelerates Aβ40 aggregation in a concentration-dependent manner and
compared the similarities to aggregates formed in HFIP interfaces [93]. While near-CMC SDS
promoted β-sheet conformations and fibrillar aggregates, micellar SDS above the CMC
stabilized Aβ40 in an α-helical conformation. Furthermore, near the CMC, Aβ40 initially
adopted an α-helical conformation corresponding to amorphous oligomers, which eventually
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converted into β-sheet fibrils over time. Similar structural transitions from α-helix to β-sheet with
a concomitant increase in fibril formation were also observed with Aβ40 in the presence of DPC
surfactants [98]. Rangachari and co-workers also demonstrated the effects of SDS on Aβ42
aggregation, which was dependent on SDS concentration [99]. However, unlike Aβ40, within a
narrow range of SDS concentrations, soluble Aβ42 oligomers were formed along a pathway
different from fibril formation, which was strictly dependent on the CMC of SDS [99]. This
observation parallels the one on well-characterized, 60 kDa ‘Aβ globulomers’ which are also
formed along a pathway that is independent of the fibril formation pathway [100, 101]. It is
noteworthy that globulomers are generated in the presence of 0.2% SDS, which is close to its
CMC. Moreover, globulomers are shown to be neurotoxic by specifically blocking long-term
potentiation in rat hippocampal slices [100]. Characterization of SDS-derived off-pathway
oligomers showed a unique structure by NMR spectroscopy [102, 103]. Studies using DHPCs as
micellar surfactants also showed modulation of aggregation based on their CMCs - enhancement
of fibril formation was observed at submicellar concentrations (below CMC), while micellar
concentrations (above CMC) stabilize Aβ in an α-helical conformation [104]. Non-esterified
fatty acids (NEFAs) have been used as model surfactants to investigate their effects on Aβ42
aggregation. Similar to those observed with SDS, NEFAs also induce concentration-dependent
effects on Aβ. Three broadly categorized regimes based on the respective CMCs of NEFAs such
as below, near and above CMC, either augmented or inhibited Aβ42 aggregation [105]. Only at
near and above the CMCs did NEFAs induce oligomers of Aβ42 via alternative pathways, while
enhancement of fibril formation was observed below the CMC [105, 106].
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c.

Modulation of aggregation by lipids and membrane constituents.
Evidence for lipid involvement in Aβ modulation. The effects of Aβ interaction with lipids

are diverse. Perhaps the most significant of them all is the ability of membrane lipids to modulate
Aβ aggregation pathways in generating polymorphic aggregates and many oligomer strains.
Numerous reports over the last decade using reconstituted phospholipid vesicles indicate
formation of aggregates along off-fibril forming pathways, paving a way for the generation of
structurally-diverse oligomers [107-109]. Recently, Aβ42 aggregation on SUV and large
unilamellar vesicles (LUV) from POPC lipids showed formation of polymorphic aggregates with
distinct biophysical characteristics [110]. In this study, LUVs with high POPC concentrations
suppressed amyloid formation that affected fibrillation kinetics, as opposed to those with low
POPC concentrations, demonstrating the effect of concentration gradients along the liposome
surface in modulating aggregation pathways. To investigate the effect of membrane thickness on
Aβ aggregation, Korshavn et al used bilayers formed by the short-chain 1,2-dilauroyl-sn-glycero3-phosphocholine (DLPC) lipid as a model for disease bilayers, while 1,2-dioleoyl-sn-glycero-3phosphocholine (DOPC) as a model of normal bilayers [111]. They found that DLPC-assisted
oligomers could disrupt the membranes more effectively than those generated from POPC
vesicles, providing evidence for the deleterious effects of reduced membrane thickness. In one
report, zwitterionic lipid vesicles not only promoted Aβ42 aggregation, they did so by interacting
specifically with the growing fibrils, showing aggregate-specific interaction of these lipids [85].
Furthermore, these lipid vesicles were thought to augment monomer-dependent secondary
nucleation at the surface of existing fibrils and facilitate monomer-independent catalytic
processes consistent with fibril fragmentation and concomitant secondary aggregation pathways
[85]. In a different study, it was also noted that Aβ aggregates formed in solution could present a
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different structure and toxicity upon interacting with the membranes [112]. It appears as though
PG lipids modify the aggregation process and induce toxic oligomers independently from the
fibrils along ‘off-pathways’, and their formation is enhanced by the presence of OH groups on
the membrane surface [113]. In our laboratory, we have demonstrated the generation of offpathway oligomers in the presence of NEFAs, which show distinct biophysical and pathological
properties from on-pathway fibrils [114-116]. We have also shown that the aggregation pathway
is dependent on the surfactant-Aβ ratio [105, 117]. Thus, given the mobility of cell membranes
and lipid rafts in cellular environments, because of which charge concentration variations
develop along the cell surface, it is highly likely that such surfactant interfaces are able to induce
similar effects on Aβ aggregation. Some of the aforementioned reports establish the fact that the
physicochemical composition and concentration of the membranes lead to different specificities
of interaction among Aβ aggregates, and promote aggregation in various ways. The data also
suggest that oligomers formed along off-fibril formation pathways, which may structurally differ
from their on-pathway counterparts, could exhibit different interaction regimes with the
membrane.
Modulatory effects were also observed for physiological lipids derived from endogenous
sources. First, toxic oligomeric Aβ has been observed in patients with AD [118], HCHWA-D
[119], and after fatal head injury [120] were found to be associated with membrane lipids as
complexes, suggesting a strong interaction between Aβ oligomers and lipids. Aβ deposition in a
form bound to plasma membranes resulted in the formation of non-fibrillar diffuse aggregates
[121]. In their investigation into the interactions of Aβ with GM1-containing liposomes, Hayashi
and co-workers observed that Aβ peptides showed altered aggregation kinetics with detectable
protofibrils [57]. They concluded that this is due to the altered conformation adopted by Aβ in
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the presence of liposomes, which drives the aggregation into an alternate pathway. Aβ42
interactions with brain-derived lipids also resulted in an exclusive formation of small aggregates
without any fibrils, suggesting generation and stabilization of off-pathway oligomers. A similar
observation was also made with the co-incubation of Aβ with lipid rafts isolated from brain
tissues in which a rapid formation of tetrameric Aβ was identified without the appearance of
fibrils even after long incubation times, indicating the generation and stabilization of oligomers
potentially as an off-pathway species [122].
Evidence of modulation based on temporal models. Modulation of aggregation pathways
to populate both oligomers and fibrils was also observed using non-physiological models of
anionic, cationic and neutral surfactants, further emphasizing the potential role of surfactants in
the modulation of aggregation [123, 124]. Figure 3 summarizes the dynamics of Aβ-surfactant
interactions reported earlier [117]. One of the main signatures of oligomers formed along the offfibril formation pathways is the temporal kinetics. ‘Off-pathway’ aggregates tend to have a
longer half-life and are slow in converting to fibrils because of their potential stabilization in
kinetics traps (Figure 4). To gain insights into the formation and decay of such aggregates,
temporal modeling is necessary. Over the years, mathematical models and simulations have
provided some important insights into the complex temporal behavior of Aβ aggregation and
modulation, but such models largely remain sparse. Mathematical models have been applied to
simulate the kinetics of different types of protein aggregation pathways including amyloid
proteins [125-128]. Such models can be broadly categorized into kinetic, empirical and their
variants such as the Finke-Watzky (F-W) kinetic model [129]. Unfortunately, very few models
have considered amyloid and lipid/membrane interactions and their effects in protein
aggregation. In her paper, Murphy stated the urgency and importance of such modeling
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approaches[130]: “Elucidation of the intricate kinetic interplay between amyloidogenesis and
membranes provides a challenge that will need to be addressed to completely ascertain the role
of membranes in amyloid disease pathology.” To our knowledge, the first mathematical
formulation to consider temporal modulation of aggregation involving competition between onand off-pathway was presented by Powers et al [131]. The specific effects of lipids/membranes
on the structure of Aβ oligomers were not studied in this work; however, the bulk effects of
lipids/membranes on aggregation behavior were modeled through fitting the experimental data.
In this model, the monomers were considered to aggregate via two different, mutually exclusive
pathways involving fibril formation (on) and oligomer formation (off). The off-pathway
considers structurally different monomers (formed by membrane/lipid interactions) that proceed
to form higher molecular weight oligomers that are structurally different from their on-pathway
counterparts. This study elegantly demonstrated the see-saw effect of two mutually competing
pathways, laying a foundation for simulating such dynamics in Aβ aggregation. Friedman et al
modeled dynamics of amphipathic peptide aggregation in the presence of surfactants [132]. They
showed that there are two specific states, aggregation prone and aggregation protected, which
correlate with the extent of aggregation. This work further supports the premise that by altering
surfactant to peptide ratio one could generate different aggregates. Recently, our work on Aβ –
NEFA interactions considers a modification of the Powers’ model to incorporate the effects of
fatty acids on fibril formation and off-pathway micellar dynamics [117]. In this work, the
combined on-pathway and off-pathway dynamics were modeled. The models from these
computations establish a competition between the on- and off-pathway reactions with the
outcome of aggregation pathway clearly dependent upon the surfactant concentration and phase
transitions [117].
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Membrane components involved in the modulation of Aβ aggregation. Despite the
establishment of possible alternative pathways of aggregation and stabilization of oligomers, it
remains unclear what molecular factors precisely control Aβ to adopt multiple aggregation
pathways. However, many reports do suggest several key players that may play a role in the
modulation of aggregation. An early report on Aβ aggregation in the presence of different subcellular organelle membranes showed accelerated fibril formation by endosomal and lysosomal
membranes while it was inhibited by Golgi membranes, which promoted oligomers exclusively
[133]. This report brought out the fact that lipid constitution could be key in dynamic regulation
of Aβ aggregation pathways. In another report, the investigators show that the presence of
cholesterol within membranes influences the membrane fluidity, which in turn could control the
outcome of their interactions with Aβ leading to the adoption of alternate aggregation pathways
and polymorphic aggregates [134]. Several other reports have indicated both GM1 and
cholesterol as key factors affecting the Aβ fibrillation on membranes. Aβ is known to recognize
cholesterol-dependent clusters of GM1-containing liposomes [135], and aggregation kinetics and
pathways are found to be strictly controlled by cholesterol and ganglioside amounts within the
liposomes [58]. Although the nature of GM1 ganglioside interaction with Aβ remains
controversial, the involvement of GM1 gangliosides in Aβ aggregation was unambiguously
established when pretreatment of brain-derived GM1-containing liposomes with CTxB, a GM1
ligand, showed inhibition of Aβ fibrillation [136]. Furthermore, liposome-containing clusters of
highly dense GM1 transformed Aβ into toxic oligomers without noticeable fibrils, indicate the
modulatory effects of GM1 on Aβ aggregation [137-140]. In a MD simulation study, GM1
interactions with Aβ and POPC and palmitoyl-oleoyl-phosphatidyl ethanolamine (POPE)
membranes lead to the release of Aβ from the membranes, further envisaging the diverse effect
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GM1 can cause on Aβ [141]. In addition, single molecule experiments on live neuroblastoma
cells showed that interaction of gangliosides with Aβ42 led to the formation of at least two
oligomeric forms with distinct biophysical and structural differences that show different
cytotoxicities [140]. Mechanistically, ganglioside clusters seem to offer a unique platform at
their hydrophobic/hydrophilic interface for binding of Aβ molecules and confining their spatial
movements to promote aggregation on the ganglioside clusters [142]. Furthermore, membrane
curvature also seems to play a role in modulating aggregation [143], which parallels some of the
observations on membrane rigidity and fluidity both as cause and consequence of Aβ interactions
[144-146]. In a recent review, Cebecauer et al. elegantly presented a unifying view on the
concentration-dependent modulatory effects of gangliosides on Aβ aggregation and oligomer
formation [147]. Furthermore, simulations also reveal and support experimental observations that
chemical composition of the membrane also affects the Aβ-lipid interactions. For example, low
cholesterol content and increased membrane fluidity results in partial Aβ membrane insertion,
while at high cholesterol content, Aβ diffuses into a more rigid membrane resulting in higher Aβ
membrane associations [147]. In a separate study, Evengelisti et al studied the cytotoxic effects
of protein oligomers on membranes and came to the conclusion that toxicity not only depends on
the nature of oligomers but also on the chemical composition of the membranes that they interact
with [148]. The same principle seems to hold true for other amyloid proteins including Aβ.

Consequence of Aβ-lipid interactions
a.

Cellular toxicity
Three broadly categorized mechanisms of oligomer-induced neurotoxicity have been

revealed by prior research [149]. a) extracellular Aβ aggregates can bind to various receptors
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leading to the activation of signaling pathways. b) Aβ oligomers can form membrane pores or
channels [64] leading to cell death, known as the “channel hypothesis” [150, 151]. c) Oligomers
can be transported within the cells to induce dysfunction of mitochondria, lysosome and
breakdown of other cellular processes. While these mechanisms have been recently reviewed by
Kotler et al and Kayed et al [152] and [149], there are a few points worth noting here. First, the
receptor-mediated mechanism postulated by many reports involving receptors such as advanced
glycation end (AGE) products, nerve growth factor (NGF), NMDA, and NF- κB, underscores the
involvement and importance of structurally diverse oligomers in neurotoxicity. A report by
Kourie et al. investigated over 100 channels formed by Aβ40, which could be grouped into one
of four categories based on conductance, kinetics, selectivity, and pharmacological properties of
the pores [153]. This report showed that heterogeneity of Aβ can manifest in part to the pore
forming structure of aggregates and their toxicity. More recently Serra-Batiste and co-workers
generated a 60 kDa oligomer of Aβ42 in high concentrations of DPC micelles, which upon
addition to lipid bilayers formed β-sheet rich nanopores [154]. These oligomers were similar in
size to the SDS-generated Aβ globulomers, which have been shown to inhibit long-term
potentiation in hippocampal slices [100]. This reveals that lipids can mediate the formation of
pore-forming oligomers, which are implicated in neurotoxicity. Another method by which Aβ
induces toxicity is by modulating membrane fluidity and conductance. Increase of membrane
conductance by several different soluble oligomers (and not monomers or fibrils) was reported,
and occurred without the formation of pores [155]. A report by Kremer et al. on membrane
fluidity changes during Aβ aggregation revealed that aggregates, but not monomers, decreased
membrane fluidity, the extent of which could be correlated to aggregate growth [144], in
agreement with other reports [156, 157]. Vestergaard et al. have investigated the effect that Aβ
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aggregates have on modulating membrane morphology and fusion events, and revealed that
Aβ42 oligomers localize more closely than fibrils to mediate fusion of LUVs with GUVs [158].
Furthermore, Aβ42 oligomers have also been shown to promote oxidative lipid damage [159]
and disrupt membrane integrity [111, 113]. The C-terminal fragment (29-42) of Aβ has been
shown to form β-sheet aggregates in the presence of lipid bilayers (PC/PE (2:1) SUVs), which
induced cellular apoptosis by fragmenting DNA and activating Caspase-3 in PC-12 cells [160].
Along similar lines, Marzesco et al. have demonstrated the potency of membrane-associated Aβ
through inoculation in transgenic mice [161]. Work from Wang and co-workers has shown that
Aβ-induced toxicity can be reduced by inhibiting cholesterol and ganglioside synthesis in PC-12
cells [162]. Some of the aforementioned reports signify the roles of a wide variety of oligomer
assemblies with distinct conformations, which were generated under the influence of membrane
lipids that manifest in a wide variety of different cellular responses depending oligomer
structure.

b.

Oligomer strains and phenotypic outcomes
A wave of recent research, driven by pathologic similarities between prion diseases and

AD [163], supports the hypothesis that corruptive protein templating, or seeding, is a prime
mover of disease propagation. Although it is unclear whether AD is infectious as are prion
diseases, Aβ, like prions, can form polymorphic and polyfunctional strains [51]. Several lines of
evidence collectively argue that aggregated Aβ in the brain extract is critical for in vivo seeding
and the phenotype of the induced Aβ deposits mirrors that of the deposits in the extract,
suggesting an Aβ-templating mechanism [48]. Indeed, a large body of work has demonstrated
that intracerebral injection of endogenous Aβ seeds induces widespread deposition of Aβ in
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transgenic mice [47-53]. Inoculations in such experiments used either Aβ-laden brain
homogenates or exogenous fibrils as seeds. Strain-specific propagation of aggregates and their
eventual physiopathological fates are starting to correlate with the structure of the propagation
units [164-167]. Recently, the Tycko laboratory elegantly established that phenotype differences
could indeed emerge in part from Aβ fibril structure and morphology by propagating fibrils
using brain derived fibrils as seeds [42, 43]. However, correlation between oligomer strains and
fibril morphology vis-à-vis phenotypes remains elusive. Heterogeneity and diversity among
oligomers, as well as the difficulty in their isolation as discrete units has, to a large extent,
impeded our understanding of oligomeric structures and their behavior. This is especially true in
the context of diverse strains generated in the presence of lipids, which remains largely
unexplored. Other manifestations of oligomer strains may involve cross-propagation of other
amyloidogenic proteins leading to exacerbation and/or clinically observed co-pathological
phenotypes [168-171].

Summary and Perspectives
It has now been established that many interacting partners including lipids, metal ions,
proteins and natural products influence the structure and aggregation of Aβ. Lipids are perhaps
the most important and are the very first family of molecules to interact with Aβ mainly because
of their perpetual association. As detailed above, lipids and Aβ can reciprocally affect each other.
While Aβ can affect lipid structure and cause membrane disruption, pore formation and damage,
lipid constitution and its physicochemical character can induce conformational changes to Aβ
and catalyze the formation of diverse oligomers. Being an IDP, the structural plasticity of
monomeric Aβ, together with its amphipathic character, makes it highly susceptible for structural

21

transitions and modifications by lipids with significant physiological consequences. Lipid-Aβ
interactions have particularly become relevant in light of the recent findings that similar to
prions, polymorphic aggregates could behave as distinct strains in imparting phenotypic
differences in AD brains [167]. The conformationally-distinct oligomers seed Aβ aggregation by
recruiting disordered monomers towards aggregates with specific morphology. One of the
defining events in the generation of stable, structurally-distinct oligomer seeds during the early
stages of aggregation is the interaction of monomers with lipids. As elaborated above,
membranes play a crucial role in initial structural transitions of Aβ. Depending on the nature of
interactions between Aβ and membranes, oligomer seed-dependent propagation of aggregates
towards various different structural forms results in discrete, structure-based cellular responses.
We now can realign our ideas on how membranes and lipids could influence the
aggregation and consequently AD pathogenesis. As schematically shown in Figure 4a, temporal
evolution of purely homotypic Aβ aggregation displays a sigmoidal growth curve (orange trace;
Figure 4a). Depending on parameters such as charge distribution, phase transition, rigidity, and
hydropathy, surfactants can alter this temporal evolution of aggregates either by augmenting or
inhibiting it (dashed lines; Figure 4a). One obvious consequence of such effects is the generation
of conformationally-changed aggregates, which may propagate their structure in many ways
leading to distinct strains. This phenomenon could also be understood based on a thermodynamic
perspective also as shown in Figure 4b. Here, the so called ‘aggregation funnel’ in orange
represents purely homotypic Aβ aggregation without the influence of surfactants. The
introduction of heterotypic interactions changes the free energy landscape to accommodate and
direct many conformational strains into deeper kinetic pits (green area; Figure 4b). Scenarios by
which surfactant-mediated strains can be generated are schematically depicted in Figure 5.
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Monomer interaction with different surfactant composition and chemistry may lead to the
formation of oligomer strains, which can propagate into morphologically-distinct fibril strains
(Figure 5). Such strains could interact and propagate differently to generate a multitude of strains
with potentially diverse pathological effects. Keeping such a picture in mind, one can see a
correlation between dynamic changes in aggregation and diversity in cellular response of Aβ
aggregates. The diverse cellular effects in turn emerge from diversity in aggregate structures, visà-vis strains. Systematic structure-receptor correlations are yet to be clearly established, which
may provide a much deeper understanding into the emergence of phenotypic differences from
conformational strains. Nevertheless, as described above, a careful analysis of the large volume
of literature on Aβ-membrane interactions generated over 2-3 decades indicates a conspicuous
pattern involving a modulatory role and a catalytic role of surfactants in generating key oligomer
strains. However, more needs to be done to ascertain unambiguously a clear cause-and-effect
role of surfactants on phenotypic divergence in AD, which perhaps holds the fundamental basis
for all Aβ-related pathologies.
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FIGURES

Figure 1: Aβ generation by sequential protease cleavage involving β- and γ-secretases.
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Figure 2: Protein sequence of Aβ1-42 protein (a) and schematic of aggregation reaction involving pure
homotypic (Aβ-Aβ) interactions.

37

Figure 3. Schematic diagram showing modulation of Aβ aggregation pathways by micelle-forming lipids
(adapted from [117]). Lipid and surfactants show dynamics involving three categorized phases depending
on their equilibrium concentrations: below critical micelle concentrations (CMC), they exist
predominantly in the non-micellar form while at high CMC they are present as micelles. Near their
CMCs, they exist in unstable and dynamic “pseudo-micellar” form. Binding of Aβ to these forms could
change the lipid phase-transition dynamics that result in modulation of aggregation pathways distinctly.
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Figure 4. Kinetic and thermodynamic profiles of Aβ aggregation pathways in the absence (orange) and in
the presence of (green) surfactants. a) Homotypic aggregation (Aβ-Aβ) in the absence of any interacting
partners such as lipids, typically displays a sigmoidal growth curve (orange) with lag phase, growth phase
and saturation (on-pathway). Heterotypic aggregation (Aβ-surfactants) is significantly altered
(represented as dashed lines along a green background) depending on the nature of lipids (off-pathway).
Such alteration of pathways leads to different oligomer and fibrils strains. b) Aggregation funnel
represented in terms of energy landscape for homotypic (orange) and heterotypic (green) interactions.
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Figure 5: Schematic representation of interactions between Aβ and surfactants leading to strain
generation. Based on the many reports detailed in this manuscript, the interaction of Aβ monomers with
lipids are initiated by the surface interactions, which are dictated by the physicochemical characteristics
of lipid head groups and other molecule present on the membrane surface. Various hexagonal structures
on the surface indicate this aspect. The hexagonal structures embedded in the membrane represent
cholesterol. Aβ undergoes conformational changes based on the nature of the lipid which generates
different conformational oligomer strains (denoted here as different shapes of yellow structures. Each
strain can propagate their structures resulting in polymorphic fibrils.
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